乳腺癌分期IORT
innovationMADE BY ZEISS
为保乳治疗提供风险适应选择。 蔡司 IORT解决方案
innovationMADE BY ZEISS

乳腺癌

了解更多

销售问询

有关购买我们产品的任何疑问?

价格要求

我们的销售团队稍后会联系您。

安排咨询时间

我们的专家稍后会联系您。

客户关怀

关于产品,您需要协助吗?

相关话题

  • 1 Vaidya, J. S., Wenz, F., Bulsara, M., Tobias, J. S., Joseph, D. J., Keshtgar, M., … Baum, M. (2014). Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet, 383(9917), 603–613.
  • 2 Vaidya, J. S., Joseph, D. J., Tobias, J. S., Bulsara, M., Wenz, F., Saunders, C., … Baum, M. (2010). Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. The Lancet, 376(9735), 91–102.
  • 3 Vaidya, J. (2013). “1-stop” radiotherapy could offer an alternative to lengthy and inconvenient post-surgery procedures for breast cancer.